Method for preparing agent showing cholagogue action. RU patent 2465000.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, specifically to an agent showing cholagogue action. A method for preparing the agent showing cholagogue action consisting in the fact that ground sandy everlasting blossom, nosebleed herb and peppermint leaves are mixed with coriander fruit, extracted in 40% ethanol by multistage counterflow extraction, settled, filtered, condensed under certain conditions.

EFFECT: agent prepared by the method described above shows high pharmacological activity and stability.

1 dwg, 3 tbl, 13 ex

IPC classes for russian patent Method for preparing agent showing cholagogue action. RU patent 2465000. (RU 2465000):

B01D11/02 - of solids

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K36/534 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

A61K36/28 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

A61K36/23 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

Another patents in same IPC classes:

Method for preparing borneol from waste fir wood green extractives / 2464035
Invention refers to pharmaceutical and cosmetic industry, particularly to a method for preparing borneol. The method for preparing borneol from a hydrodistillate of a lipid portion of fir wood green extract involving saponification of the hydrodistillate in an alcohol solution of alkali, heating, stripping of alcohol and a portion of volatile ingredients, washing in hot still bottom water, separation of still bottom from an aqueous layer, crystallisation of borneol, filtration, washing in an organic solvent, re-crystallisation from mixed ethylacetate and petroleum benzene under certain conditions.

Method for preparing shelf fungus extract / 2464032
Invention refers to pharmaceutical, food and cosmetic industry, particularly to a method for preparing a shelf fungus extract. The method for preparing a shelf fungus extract involving soaking of ground shelf fungus in an aqueous solution containing 5-15% dimethylsulphoxide and 2-8% sodium hydroxide under certain conditions, filtration and removal of the aqueous solution followed by staged extraction of the prepared raw material in water, filtration of the extract to provide a first degree of extraction and pulp to be extracted to provide a second degree of extraction, and merge of the extracts.

Method for preparing shelf fungus extract / 2463064
Invention refers to pharmaceutical and cosmetic industry and concerns preparing shelf fungus extract. A method for preparing shelf fungus extract involving extraction of ground shelf fungus in sodium or potassium hydroxide under certain conditions; the prepared extract is filtered.

Method for preparing biologically active concentrate of preserved antlers / 2461384
Invention refers to pharmaceutical industry, namely a method for preparing a biologically active concentrate of preserved antlers. The method for preparing the biologically active concentrate of preserved antlers consisting in grinding and two-stage enzymatic hydrolysis of antlers to be followed by extraction; at the first stage hydrolysis in the presence of the pepsin enzyme is followed by centrifugation and filtration of the hydrolysate, while the second stage includes enzymatic hydrolysis of cake prepared by the first stage of fermentation in the presence of the papain enzyme; further the cake prepared by is extracted centrifugation and filtration of the hydrolysate after the second stage of fermentation that is followed by centrifugation and filtration; thereafter all the filtrates are dried under certain conditions.

Method for producing of preparation possessing anxiolytic activity / 2460534
Invention refers to pharmaceutics, particularly a method for producing a preparation possessing anxiolytic activity. A method for producing the preparation possessing anxiolytic activity wherein ground hop cones are sequentially extracted in 60-70% ethanol under certain conditions; thereafter aqueous-alcoholic extracts are concentrated under vacuum; stillage residue are combined with the aqueous extract, filtered, boiled out, purified by separation, boiled out additionally, dried in a vacuum drier and ground.

Method for recycling wood green malus baccata / 2459628
Invention refers to perfumes and cosmetics, pharmaceutical, wood chemical industry. The method for recycling wood green Malus Baccata involving grinding, drying, extraction in 60-70% ethanol under certain conditions, settling of the extract, separation of precipitated raw wax, distillation of a solvent from the extract.

Method of producing fullerene c<sub>60</sub>

Method of producing fullerene c₆₀ / 2456233
Invention can be used in medicine, biology, nanoelectronics, when manufacturing optical devices, as well as in standardisation and metrology. An initial fullerene extract containing C60, C60O, C70 C76/78 and C84 is enriched with fullerene C60 to 96±2% via fractional concentration. The solution of the obtained concentrate then undergoes chromatographic purification on activated carbon in an aromatic solvent until achieving concentration of fullerene C60 in the eluate of not less than 99.7%. The solid C60-rich product is extracted from the eluate and then subjected to vacuum sublimation heat treatment at pressure 10-2-10-3 torr and temperature 700-800°C for 90±30 minutes.

Method of granulated material feed / 2456049
Invention relates to mass exchange and may be used in mass exchange hardware in chemical, pharmaceutical and other industries. In compliance with proposed method, granulated material is injected into circulation flow. Said circulation flow area is varied and directed along zigzag line. Note here that raw granulated material is fed into zigzag top branch, its inclination exceeding the angle of material natural slop in fluid.

Method for preparing agent showing anti-inflammatory action / 2456015
Invention refers to pharmaceutical industry, particularly a method for preparing an agent showing anti-inflammatory action. A method for preparing the agent showing anti-inflammatory action by extraction of grinded European aspen leaves in 40 % ethanol by multistage counterflow extraction in the specific environment; the combined extract is settled; the purified extract is thickened under vacuum, dried up in a vacuum oven to produce a dry extract and grinded.

Antimelancholic medicine prepared with jujuba camp materials / 2456014
Invention refers to pharmaceutical industry, particularly to a medicine for treating depression. The oral medicine for treating depression prepared from a jujuba extract containing jujube cyclic adenosine monophosphate (jujuba cAMP) and an additional ingredient taken from a group consisting of a pharmaceutically acceptable carrier, an additive, an adjuvant and combination thereof. A method for preparing jujube cyclic adenosine monophosphate (jujuba cAMP) taken as an ingredient of the medicine for treating depression, involving the stages: (a) jujube extraction in water and alcohol to produce a primary extract, (b) primary extract purification to produce a secondary extract wherein the jujuba cAMP concentration in the secondary extract is higher than that in the primary extract wherein the stage (b) is performed by jujuba cAMP chromatography of the primary extract with the use of macroporous resins bound with an aldehyde group.

Quinazoline derivative and pharmaceutical preparation / 2464263
Invention relates to a quinazoline derivative of general formula [1], or a pharmaceutically acceptable salt thereof [1], where R1-R6 assume values given claim 1, except compounds in which R5 is hydrogen and R6 is -NH2. The invention also relates to a pharmaceutical composition having the activity of an antipruritic agent, containing as an active ingredient said quinazoline derivative or pharmaceutically acceptable salt thereof.

Agent of saussurea ds plants possessing hepatoprotective action / 2464036
Invention refers to pharmaceutical industry, particularly to an agent possessing hepatoprotective activity and an ability to normalise the hepatic function. The use of a ground elevated part of Saussurea plants or an aqueous or aqueous-alcoholic or supercritical fluid extract of the elevated part of Saussurea plants as the agent possessing hepatoprotective activity and the ability to normalise the hepatic function.

Use of modified cyclosporines / 2463071
Group of inventions refers to medicine, particularly the use of non-immunosuppressive cyclophilin-binding cyclosporine for preventing or treating transplantation-related cirrhosis wherein cyclosporine (I) binds to human recombinant cyclophilin with a binding constant (BR) making less than 0.7 wherein BR represents a common logarithm of IC50 cyclosporine to IC50 cyclosporine A relation in concurrent experiment when evaluating by ELISA procedure; and (II) has activity in lymphocyte assay in the mixed culture making no more than 5% as compared with cyclosporine A activity (cl. 1) of the patent claim. There are also disclosed a pharmaceutical composition and a pharmaceutical combination containing cyclosporine under cl. 1.

Phospholipid nanoform for oral application (sachet) and method for preparing it (versions) / 2463057
Invention refers to medicine, pharmacology and concerns an oral granulated dosage form in sachets containing phospholipids in the form of particles of small (20-30 nm) diameter, glycyrrhizic acid and its salt (including sodium glycerrhizinate), as well as carbohydrate (including maltose) and excipients (granulation, anti-clotting and powder), as well as to a method for preparing it by mixing fat and water phases of herbal phospholipids and acceptable carbohydrate to prepare an emulsion, cooling to 50°C and passing through a microfluidiser for 4-5 cycles under pressure 2000 atm.

Agent showing hepatoprotective action, and method for preparing it / 2462259
Invention refers to pharmaceutical industry, specifically to an agent showing hepatoprotective action. The agent showing hepatoprotective action of a herbal polyphenol extract of Amur maackia heartwood (Maxar) which represents an aqueous solution of Maxar in the molecular-capsulated form in the form of a water-soluble associated with a surfactant having a specific hydrophilic-lipophilic balance. A method for preparing the agent showing hepatoprotective action by Maxar homogenisation in the melt surfactant under certain conditions to produce the molecular-capsulated form of the end product.

Method of treating patients with chronic liver diseases in stage of latency and degree i manifested stage of hepatic encephalopathy / 2462251
Invention refers to medicine and aims at treating the patients with chronic liver diseases (CLD) in the stage of latency and degree I manifested stage of hepatic encephalopathy. The preparation Essentiale forte N is used. It is combined with prescribing the preparation Mucofalk. The course is 28-30 days.

Method of treating chronic viral hepatitis c / 2459629
Invention refers to medicine, namely hepatology and may be applicable in treating chronic viral hepatitis C. That is ensured by introducing short-lived interferon-alpha (IFN) and the nucleoside analogue Ribamidil in the patient with an initial average week dosage specified in the range of 10.5 to 21.0 mil. IU depending on the level of native patient's interferon-alpha. Interferon-alpha is introduced with at least twice gradually increase of the average week dose to 21.0 to 84 mil. IU. Over the whole period of introducing IFN, the patient is prescribed with additional antiviral preparations - an interferon inducer, as well as an amantadin preparation or a glycyrrhizic acid preparation. It is combined with a support therapy involving the introduction of T-cell immunity stimulators and preparations for correction of side effects. The presence of blood viral ribonucleic acid is occasionally controlled and the introduction of Ribamidil is started in a daily dose of 800-1200 mg from the third month from the beginning of treatment if observing the presence of ribonucleic acid or from the tenth month if observing the absence. The treatment is continued until at least a 12-month aviremia period is achieved.

Method of prevention and treatment of liver disease with application of receptor a<sub>2b</sub> antagonists

Method of prevention and treatment of liver disease with application of receptor a_2b antagonists / 2457842
Group of inventions relates to field of medicine. Method of treatment and prevention of liver fibrosis includes peroral introduction to mammal of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione. Method of reducing hepatotoxic side effects of chemical therapy or radiotherapy includes peroral introduction to mammal who underwent such treatment of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl) -1,3,7-trihydropurine-2,6-dione.

Granule and method for making thereof / 2456980
Invention refers to pharmaceutics. A pharmaceutical granule is spherical or spheroidal and has volume density 0.6-1.3 g/ml and disintegration 0.5-5 minutes. Active pharmaceutical ingredients are preparations of Traditional Chinese Medicine, herbal preparations or their extracts with a nucleus made of an extract of Traditional Chinese Medicine or herbal preparations, and a pharmaceutically acceptable carrier. The content of the pharmaceutically acceptable carrier with respect to total granule weight makes 10-60 wt %. The granule diameter can be equal to 700-1500 mcm. The granule nucleus diameter can be equal to 200-750 mcm. The granule can be also coated with a layer of 2-5 wt % with respect of total granule weight. A method for making the granules consists in introducing initial granules into a layer of a fluidised material as an excipient; the active pharmaceutical ingredients are prepared in the form of a suspension or a solution of the viscosity controlled within 6.0-9.8 MPa·s with using a viscosity-control agent; then they are sprayed over a surface of the initial granule for making a finished granule.

Method for preventing and treating hepatic consequences of ischemia / 2456678
Liver is resected in an animal experimentally. A pharmacological protection is presented by Mexicor and Serotonine Adipinate. On the operation day, 5% Mexicor is used in the form of intravenous slow stream introductions twice - 35 minutes before the operation in a dose of 5 mg/kg of weight and 11 hours after the first introduction in a dose of 7 mg/kg of weight. Serotonine Adipinate dissolved in 5 ml of isotonic solution NaCl is used in the form of intravenous slow stream introductions three times - 1 hour before the operation in a dose of 0.15 mg/kg of weight, 2 hours after the first introduction in a dose of 0.2 mg/kg of weight, 10 hours after the first introduction in a dose of 0.1 mg/kg of weight. During the postoperative period, Mexicor and Serotonine Adipinate are introduced for 8 days. Mexicor is introduced three times a day at 9 o'clock in a dose of 2.5 mg/kg of weight, at 15 o'clock in a dose of 1.5 mg/kg of weight, at 21 o'clock in a dose of 6 mg/kg of weight. Serotonine Adipinate is introduced twice a day - at 8 o'clock in a dose of 0.15 mg/kg of weight, at 17 o'clock in a dose of 0.1 mg/kg of weight.

Method for immunoprophylaxis of respiratory diseases in calves / 2464999
Invention refers to veterinary science. A method for immunoprophylaxis of respiratory diseases in calves involves immunisation with an associated vaccine for parainfluenza-3, infectious rhinotracheitis and bovine viral diarrhoea viruses in a combination with the use of an alcoholic solution of a herbal raw material as an agent for non-specific prophylaxis with the herbal raw material presented by a mixture of equal proportions of purple Echinacea herb and blossom clusters, Syrian rue herb, tillet blossom and common licorice roots which is imbedded in 70% ethanol in relation 1:10, kept in a dark place at temperature 18-20°C for 7 days; the prepared tincture is prescribed orally in the form of 7-8% aqueous solution 1.5-2.0 ml/kg of animal's body weight for 15 days with immunising calves of 60 days old.